Lumos Pharma, Inc.
NASDAQ Global MarketRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Lumos Pharma, Inc. (NASDAQ: LUMO) is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for rare diseases, particularly those associated with growth hormone deficiencies; its lead product candidate is LUM-201 (ibutamoren), an oral growth hormone secretagogue that stimulates endogenous pulsatile growth hormone secretion from the pituitary gland for the treatment of pediatric growth hormone deficiency (PGHD), offering a potential alternative to injectable recombinant human growth hormone therapies. The company's pipeline centers on LUM-201, which has received Orphan Drug Designation in the US and EU, has been studied in over 1,300 patients, and demonstrated positive topline results from Phase 2 OraGrowtH210 and OraGrowtH212 trials meeting all primary and secondary endpoints; Lumos Pharma plans to expand its portfolio through strategic partnerships, in-licensing, and acquisitions of novel rare disease candidates across endocrinology, neurology, and inborn errors of metabolism. Founded in 2012 and headquartered in Austin, Texas, the company operates primarily in the US with a global Phase 3 trial planned for LUM-201. In October 2024, Lumos Pharma entered a definitive merger agreement with Double Point Ventures LLC (DPV) for $38 million, or $4.25 per share plus a contingent value right tied to future LUM-201 milestones, positioning it to continue as a standalone subsidiary under DPV ownership with the transaction expected to close by year-end 2024; alongside this, the company aligned with the US FDA on a double-blind, placebo-controlled Phase 3 trial design for LUM-201 in PGHD, slated to commence in Q2 2025.
Lumos Pharma and Double Point Ventures Announce Successful Completion of Tender Offer and Double Point Ventures' Acquisition of Lumos Pharma
SHAREHOLDER INVESTIGATION: The M&A Class Action Firm Investigates the Merger of Lumos Pharma Inc. – LUMO
ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Lumos Pharma, Inc.
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates MMLP and LUMO on Behalf of Shareholders
LUMO Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Lumos Pharma, Inc. Is Fair to Shareholders
Lumos Pharma Announces Abstract Accepted for Oral Presentation at the 13th Biennial Scientific Meeting of the Asia Pacific Pediatric Endocrine Society, APPES 2024
Lumos Pharma to Participate in H.C. Wainwright 26th Annual Global Investment Conference
Lumos Pharma, Inc. (LUMO) Q2 2024 Earnings Call Transcript
Lumos Pharma Reports Second Quarter 2024 Financial Results and Provides Clinical Development Update
Lumos Pharma to Report Second Quarter 2024 Financial Results and Provide Clinical Update on August 1, 2024
Lumos Pharma Announces Abstracts Accepted for Presentation at ENDO 2024
Lumos Pharma, Inc. (LUMO) Q1 2024 Earnings Call Transcript
Lumos Pharma Announces Positive End-of-Phase 2 Meeting with FDA and Reports First Quarter 2024 Financial Results
Lumos Pharma to Report First Quarter 2024 Financial Results and Provide Clinical Update on May 15, 2024
Lumos Pharma Announces Abstracts Accepted for Presentation at Upcoming Medical Meetings
Lumos Pharma Announces that the USPTO Has Granted Patent Protection for Novel Formulation of LUM-201, Extending Exclusivity to 2042
Lumos Pharma, Inc. (LUMO) Q4 2023 Earnings Call Transcript
Lumos Pharma Reports Full Year 2023 Financial Results and Provides Clinical Development Update
Lumos Pharma to Report Full Year 2023 Financial Results and Host Conference Call on March 7, 2024
Lumos Pharma to Participate in Oppenheimer's 34th Annual Healthcare Life Sciences Conference